Biopharma Use Cases & Cost Landscape

Download the White Paper

See how CareStations cut per-patient recruitment costs from $806 to $3—and reach the 120 million Americans traditional trial infrastructure can't.

The U.S. drug development model has a structural problem. Fewer than 150 institutions drive the majority of clinical trial activity, only 14% of trial protocols explicitly include diversity considerations, and the industry spends $1.89 billion annually on patient recruitment—before a single drug reaches the patients who need it most. The result is billions lost to recruitment delays, dropout rates, surveillance gaps, and missed commercial opportunity at every stage of the lifecycle.

This White Paper maps the full cost landscape across four stages of drug development—pre-clinical trial, during the trial, post-trial, and commercial—drawing on 22 industry sources to show where the current model breaks down and what community-embedded clinical infrastructure can recover. From reducing trial recruitment cost from $806 to $3 per enrolled participant, to generating real-world evidence from the 120 million Americans invisible to every existing dataset, the OnMed CareStation™ addresses the access gap that telehealth can't solve and AMC-centric infrastructure was never built to reach.

What the Brief Covers

• The cost landscape across all four stages of the drug development lifecycle: pre-clinical trial, during the trial, post-trial, and commercial.

• Where cost is concentrated today—from $5M–$20M in pre-enrollment site activation to $1.89 billion spent industry-wide each year on patient recruitment.

• The OnMed opportunity mapped to each stage: community-based recruitment, decentralized monitoring, real-world evidence generation, and in-community patient support programs.

• CareStation outcomes data: 78% of users have no primary care physician, 37% repeat usage rate, 4.96/5 patient satisfaction, and per-patient recruitment costs reduced from $806 to ~$3.

• Patient demographic breakdown by age, gender, race, and language—reaching populations largely invisible to AMC-centric trial infrastructure.